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Purpose: Haploinsufficiency through mutation or deletion of the forkhead transcription factor, FOXC1, causes Axenfeld-
Rieger anomaly, which manifests as a range of anterior segment eye defects and glaucoma. The aim of this study is to
establish whether mutation of FOXC1 contributes toward other developmental eye anomalies, namely anophthalmia,
microphthalmia, and coloboma.
Methods: The coding sequence and 3`-UTR of FOXC1 was analyzed in 114 subjects with severe developmental eye
anomalies by bidirectional direct sequencing.
Results: Four coding FOXC1 variations (two novel missense variations, one insertion, and one novel deletion) were
identified in the cohort. Two noncoding variations were also identified in the 3′-UTR. The missense mutations were c.
889C_T and c.1103C_A, resulting in p.Pro297Ser and p.Thr368Asn, respectively. The c.889C_T transition was identified
in 19 of the 100 unaffected control samples. The c.1103C_A transversion resulted in a conservative substitution in an
unconserved  amino  acid  and  was  deemed  unlikely  to  be  pathogenic.  A  c.1142_1144insGCG  change  resulting  in
p.Gly380ins, which was previously associated with kidney anomalies, was identified in 44 of the 114 affected individuals.
This variation was also present in 29 of the 87 unaffected controls and is therefore likely to be a polymorphism. A c.
91_100delCGGCGGCCG deletion resulting in p.Ala31_33del was identified in one individual. This deletion segregated
with the moderately affected mother and unaffected maternal grandfather of the proband. This deletion was identified in
one of the 307 unaffected controls.
Conclusions: Our data suggests a potential susceptibility role for FOXC1 in generating severe eye pathologies. However,
on  the  basis  of  these  results,  it  is  unlikely  that  FOXC1  mutation  is  a  major  causative  factor  of  anophthalmia,
microphthalmia, and coloboma.
Developmental  eye  anomalies  (DEA)  encompass  a
spectrum of severe structural defects of the eye caused by the
disruption of the smooth process of ocular morphogenesis
during  early  gestation  [1].  With  a  birth  prevalence  of
approximately  1  in  3,000–4,000,  DEA  are  considered  to
account  for  at  least  25%  of  childhood  visual  impairment
worldwide  [2,3].  The  most  severe  forms  of  DEA  are
anophthalmia,  characterized  by  the  complete  absence  of
ocular tissue in the orbit, and microphthalmia, which exhibits
wide phenotypic variability and causes the eye to have an axial
length  of  two  standard  deviations  below  the  age-adjusted
mean  with  variable  intraocular  abnormalities  including
coloboma [4].
A growing number of monogenic syndromes have begun
to be identified in patients exhibiting DEA including those
caused by mutations or deletions in orthodenticle homeobox
2 (OTX2), SRY (sex determining region Y)-box 2 (SOX2), H6
family homeobox 1 (NKX5-3), visual system homeobox 2
(CHX10), sonic hedgehog (SHH), retina and anterior neural
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FOXC1  is  a  member  of  the  forkhead  family  of
transcription  factors,  characterized  by  their  molecular
arrangement of two wings connecting β strands flanking one
of  three  α  helices  [28].  This  helix-turn-helix  structure
comprises the evolutionarily conserved forkhead domain of
110 amino acids through which the FOX proteins are able to
interact with DNA and translocate to the cell nuclei [29].
Forkhead genes act as critical regulators of embryogenesis,
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fold  homeobox  (RAX),  bone  morphogenetic  protein  4
(BMP4),  BCL6  co-repressor  (BCOR),  chromodomain
helicase DNA binding protein 7 (CHD7), and paired box 6
(PAX6) [5-16]. Furthermore, there are up to 400 different
chromosome  aberrations  described  in  the  various
dysmorphology databases including deletions, duplications,
and  translocations  [17-23].  Many  of  these  aberrations  are
likely to act by disrupting eye development genes and likely
to harbor additional candidate genes that can be studied to
further  understand  developmental  eye  disorders.  One
particular  example  is  the  6p25  deletion  syndrome.  This
syndrome causes deafness [24], developmental delay, facial
dysmorphology [25], brachycephaly, schizophrenia [26], and
anterior eye anomalies [23-27]. The eye anomalies are thought
to  be  due  to  a  deletion  of  the  forkhead  box  C1  gene
(FOXC1).cell migration, and cell differentiation. Disruptions within the
FOX genes have long been associated with pathogenicity and
ocular disease in particular [28]. FOXC1 whole gene deletions
or mutations within or affecting the forkhead domain through
which  FOX  proteins  are  able  to  interact  with  DNA  and
translocate to the cell nuclei [29] underlie Axenfeld-Rieger
anomalies. To date, at least 30 different missense, nonsense,
and frameshift mutations have been identified, affecting the
forkhead domain of FOXC1 in individuals presenting with the
spectrum of ocular defects associated with Axenfeld-Rieger
syndrome and anomaly (anteriorly-displaced Schwalbe’s line,
iris adhesions, iridocorneal angle dysgenesis, and corectopia
[30-44]). Approximately half of these patients also develop
glaucoma,  which  may  cause  further  visual  deterioration.
Interestingly,  both  duplications  and  deletions  of  the  6p25
segment containing FOXC1 are associated with anterior eye
malformations [25,45]. These seemingly complex genotype-
phenotype  associations  are  consistent  with  FOXC1  gene
dosage effects [46]. Intriguingly, one such study by Gould et
al.  [23]  describes  seven  individuals  with  6p25  deletion
syndrome associated with ocular dysgenesis of which two
individuals presented with microphthalmia.
Since deletions of FOXC1 have been associated with
microphthalmia [23], an investigation into the role of FOXC1
in  producing  developmental  eye  anomalies,  distinct  from
those  associated  with  Axenfeld-Rieger  syndrome,  is
important in enabling us to delimit the effect of this gene. We
therefore decided to investigate a wider role for FOXC1 in
underlying developmental eye anomalies and screened the
gene for disease-causing variations in a cohort of patients
exhibiting anophthalmia, microphthalmia, and coloboma.
METHODS
One hundred and fourteen subjects with developmental eye
anomalies  consisting  of  unilateral  microphthalmia  with
contralateral  normal  eye  or  minor  defect  such  as  myopia
(n=33); bilateral microphthalmia (n=20) including one with
bilateral  Peter’s  anomaly  and  one  with  anterior  segment
dysgenesis;  bilateral  anophthalmia  (n=12);  unilateral
anophthalmia with contralateral defect e.g., retinal dystrophy
(n=7); unilateral anophthalmia with contralateral coloboma
(n=2);  unilateral  anophthalmia  and  contralateral
microphthalmia  (n=3);  unilateral  anophthalmia  with
contralateral normal eye or minor defect e.g., myopia (n=11);
unilateral  coloboma  with  contralateral  normal  eye  (n=3);
unilateral  microphthalmia  with  bilateral  coloboma  (n=1);
unilateral  microphthalmia  with  unilateral  coloboma  (same
eye;  n=8);  unilateral  microphthalmia  with  contralateral
coloboma  (n=4);  bilateral  coloboma  (n=2);  bilateral
microcornea  (n=1);  unilateral  microphthalmia  with
contralateral  defect  e.g.,  retinal  dystrophy  (n=5);  bilateral
Peter’s anomaly with normal sized eyes (n=1); and unilateral
Peter’s anomaly (n=1) were screened for variations in the
coding region of FOXC1 (Ensembl Transcript: FOXC1–001
ENST00000380874). These individuals had been previously
screened for mutations in genes known to be associated with
anophthalmia,  microphthalmia,  and  coloboma,  including
SOX2, OTX2, SHH, and BMP4 [5,13]. Informed consent was
obtained  from  all  subjects  under  full  ethics  approval  as
previously described [5,13]. Familial DNA and ethnically
matched control DNA samples were obtained where possible
in the event of a putative causative variant being identified. A
control  cohort  of  100  Yoruba  people,  87  CEPH  (Centre
d'Etude du Polymorphisme Humain) samples, and 307 British
Caucasians were analyzed for the variations p. Pro297Ser,
p.Gly380ins,  and  p.  Ala31_33del,  respectively.  Statistical
analysis comprising a Fisher's exact test for count data was
performed on the data sets using the R software package.
Eight primer pairs spanning the exonic sequence and 3`-
UTR of FOXC1 were designed using Primer3 (Table 1) and
amplified by polymerase chain reaction (PCR) on a DNA
Thermocycler 9700 (Applied Biosystems®, Foster City, CA).
PCR was performed according to the manufacturer’s standard
protocol in 10 µl reaction volumes using the FailSafeTM PCR
System (EPICENTRE® Biotechnologies, Madison, WI) for
amplicons  FOXC1i,  FOXC1ii,  and  FOXC1iii  and  Qiagen
HotStarTaq DNA Polymerase (Qiagen®, Valencia, CA) for
amplicons FOXC1iv, FOXC1v, FOXC1vi, FOXC1vii, and
FOXC1viii under the reaction conditions detailed in Table 1.
Sequencing  reactions  were  performed  with  the  PCR
primers on ExoSAP-IT® cleaned products (USB Corporation,
Cleveland, OH) using BigDyeTM Terminator (v.3.1) Cycle
Sequencing  Ready  Reaction  Kit  (Perkin-Elmer,  Waltham,
MA) and resolved on an ABI Prism Genome Analyzer 3700
or 3100 for longer reads (Applied Biosystems®). Data were
analyzed  by  constructing  contigs  aligned  to  a  reference
sequence using SequencherTM software (v.4.5; Gene Codes
Corporation, Ann Arbor, MI). Confirmation of the sequence
changes was obtained using a second sample.
RESULTS
Four FOXC1 coding sequence alterations were revealed by
direct sequencing comprising two missense variations, one
insertion, and one deletion. Two noncoding variations were
also identified (Table 2 and Figure 1).
The deletion (c.91_100delCGGCGGCCG; Figure 2D)
caused  a  three  residue  contraction  of  the  alanine  tract
(p.Ala31_33del),  located  41  amino  acids  upstream  of  the
forkhead domain in activation domain 1 of the protein [29].
The deletion resulted in the removal of a SacII recognition site
from the PCR product. This deletion was identified in one
individual who presented with an optic disc coloboma in both
eyes with additional iris and chorioretinal coloboma in the left
eye. The moderately affected mother and unaffected maternal
grandfather  were  all  heterozygous  for  the  deletion.  Three
hundred and seven ethnically matched control DNA samples
of British Caucasian origin and the family members of the
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1368proband  (parents,  maternal  grandparents,  sister)  were
screened for the variation using a restriction digest method
exploiting the absence of the SacII restriction site. One control
sample  was  also  heterozygous  for  c.
91_100delCGGCGGCCG. These frequencies were analyzed
using  Fisher’s  exact  test  and  found  not  to  be  significant
(p=0.4678)
The first missense mutation was present in two patients,
one of Nigerian and the other of Hispanic descent. It resulted
from  a  c.889C_T  transition  (Figure  2A),  causing  a
p.Pro297Ser amino acid alteration in the protein inhibitory/
phosphorylation domain (as defined by Berry et al. [29]). This
variation resulted in the introduction of an HgaI restriction site
into the gene. One hundred ethnically matched DNA samples
of  Yoruba  descent  were  screened  for  the  variation  in  a
restriction  digest  assay  with  HgaI.  The  variation  was
identified in 19 of the control samples.
The second missense mutation, c.1103C_A (Figure 2B),
resulted in p.Thr368Asn outside any of the defined functional
domains of the protein. This variation was present in a patient
of Singaporean-Filipino descent and resulted in a conservative
amino  acid  substitution  in  a  residue,  which  was  highly
variable across species. No familial or ethnically matched
control DNA sample was available for this variant and thus
could not be investigated further. SIFT (Sorting Intolerant
From Tolerant) analysis [47] supported the low likelihood of
p.Thr368Asn being a pathogenic variant.
The final variation identified was a c.1142_1144insGCG
change  (Figure  2C),  resulting  in  p.Gly381ins,  which  was
present  in  a  heterozygous  form  in  37  individuals  and  a
homozygous form in seven individuals. This variation has
been  previously  reported  in  a  screen  of  patients  with
congenital abnormalities of the kidney and urinary tract [48].
The heterozygous form of this variation was identified in 27
out of 87 unaffected control samples and was present as a
homozygous variant in two of the control samples. Fisher’s
exact test analysis of these frequencies indicated that they
were not significant (p=0.4523)
DISCUSSION
We report the first screen of patients manifesting with severe
developmental eye anomalies for disease-causing variations
in FOXC1. Since deletions of FOXC1 have been associated
with microphthalmia [23], an investigation into the role of
FOXC1 in producing developmental eye defects distinct from
those previously associated with the mutation in this gene is
important to enable us to delimit its effect. To date, mutations
of human FOXC1 have been associated with anterior segment
dysgenesis,  iris  anomalies,  and  developmental  glaucoma.
These  phenotypes  may  arise  from  an  abnormality  in  the
migration and/or differentiation of mesenchymal cells that
contribute to the anterior segment of the eye as in the mouse.
Kume  et  al.  [49]  demonstrated  that  16.5  dpc  (days  post
coitum) Foxc1 null mice display several ocular anomalies
TABLE 2. DETECTED VARIATIONS AND DISEASE PHENOTYPE.
Variation Phenotype
Heterozygous p.Pro297Ser Unilateral microphthalmia and sclerocornea
Heterozygous p.Pro297Ser Unilateral extreme microphthalmia with cyst, contralateral myopia
Heterozygous p.Thr368Asn Unilateral microphthalmia and dense cataract
Heterozygous p.Gly380ins Multiple patients
Homozygous p.Gly380ins Multiple patients
Heterozygous p.Ala31_33del Right optic disc coloboma and left iris and chorioretinal coloboma
Heterozygous 3`-UTR 1662+1041C>T Right optic disc coloboma and left iris and chorioretinal coloboma
Heterozygous 3`-UTR 1622+396delC Bilateral microphthalmia with Rieger anomaly and
Heterozygous 3`-UTR 1622+396delC Unilateral microphthalmia with microcornea and subtotal retinal detachment
All variations detected within the patient cohort with their corresponding phenotype.
Figure 1. FOXC1 gene structure. Locations of amplicons and identified variations are displayed.
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1369Figure 2. Direct sequencing analysis of
the coding region of FOXC1. A: The
lower sequence shows the heterozygous
missense  mutation  c889C_T
(p.Pro297Ser)  identified  in  two
individuals, and the upper sequence is
the corresponding wild-type sequence.
B:  The  lower  sequence  shows  the
heterozygous  missense  mutation  c.
1103C_A  (p.Thr368Asn)  detected  in
one individual, and the upper sequence
is  the  corresponding  wild-type
sequence.  C:  The  bottom  sequence
shows the 3-bp heterozygous insertion
mutation,  c.1142_1144insGCG
(p.Gly380ins),  detected  in  37
individuals. The middle sequence shows
the  equivalent  homozygous  insertion
detected in seven individuals. The upper
sequence  displays  the  corresponding
wild-type  sequence.  D:  The  lower
sequence shows the 9-bp heterozygous
deletion,  c.91_100delCGGCGGCCG
(p.Ala31_33del),  detected  in  the
proband, mother, maternal grandfather,
and 1 of the 307 control samples, and the
upper  sequence  displays  the
corresponding wild-type sequence.
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1370syndrome (BPES) [52] and FOXE1 in thyroid dysgenesis
[53].  In  the  FOXE1/thyroid  dysgenesis  model,  there  is  a
significant association between a shorter polyalanine tract and
the manifestation of the disease phenotype. As a disease-
causing mechanism, Carré et al. [53] demonstrate that the
transcriptional  activation  of  FOXE1  with  16  alanines  is
significantly higher than FOXE1 containing 14 alanines. They
concluded that FOXE1 significantly modulates the risk of
thyroid dysgenesis occurrence through its alanine-containing
stretch and proposed a mechanism linking the polyalanine
tract containing transcription factors to disease. Interestingly,
the disease-associated variant in FOXE1 also segregates with
unaffected controls, which is similar to our observation with
the contraction of the polyalanine tract in FOXC1. Therefore,
this is consistent with the contraction of alanine tract being a
susceptibility factor rather than a disease-causing mutation.
The oligogenic basis of developmental eye anomalies is
well  recognized  and  will  only  be  resolved  when  a
comprehensive  candidate  gene  set  has  been  analyzed  for
mutations,  coding  polymorphisms,  or  copy  number
variations. In this study, we have identified several variations
affecting the coding sequence of FOXC1, some of which
could  contribute  to  phenotype  severity  and  penetrance.
Although a direct causative role for FOXC1 mutations in our
cohort of patients with developmental eye anomalies has not
been definitively shown, FOXC1 could contribute genetic
susceptibility either through contraction in the length of the
polyalanine tract or other genetic variations similar to the ones
described here.
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including a disorganized arrangement of cells in the cornea,
iris hypoplasia, unfused eyelids, and a reduced number of
mesenchymal cells in the future stromal region.
Although  an  important  role  for  FOXC1  in  eye
development is clear, the complexities of this association are
evident  through  the  lack  of  any  conclusive  genotype-
phenotype correlations; the eye phenotypes associated with
6p25  deletion  syndrome  often  exhibit  variable  penetrance
[25]. Individuals with FOXC1 mutations or deletions also
demonstrate  a  spectrum  of  phenotypic  consequences,
including the mutated allele segregating with affected and
unaffected members of the same family [36,39-41]. It has
therefore been suggested that either environmental factors
and/or modifier genes interact with FOXC1 in producing a
disease phenotype [50], and this is not uncommonly seen with
other ocular developmental genes [13].
The  level  of  phenotypic  variability  could  also  be
attributed  to  stochastic  factors  in  development  related  to
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